Your browser doesn't support javascript.
loading
Heterogeneity of Treatment Effects Among Patients With Type 2 Diabetes and Elevated Body Mass Index in a Study Comparing Group Medical Visits Focused on Weight Management and Medication Intensification.
Kobe, Elizabeth A; Crowley, Matthew J; Jeffreys, Amy S; Yancy, William S; Zervakis, Jennifer; Edelman, David; Voils, Corrine I; Maciejewski, Matthew L; Coffman, Cynthia J.
Afiliación
  • Kobe EA; Duke University School of Medicine.
  • Crowley MJ; Durham Veterans Affairs Center of Innovation to Accelerate Discovery and Practice Change (ADAPT).
  • Jeffreys AS; Division of Endocrinology, Department of Medicine.
  • Yancy WS; Durham Veterans Affairs Center of Innovation to Accelerate Discovery and Practice Change (ADAPT).
  • Zervakis J; Duke University School of Medicine.
  • Edelman D; Durham Veterans Affairs Center of Innovation to Accelerate Discovery and Practice Change (ADAPT).
  • Voils CI; Division of General Internal Medicine, Department of Medicine, Duke University Medical Center.
  • Maciejewski ML; Duke Lifestyle and Weight Management Center, Durham, NC.
  • Coffman CJ; Durham Veterans Affairs Center of Innovation to Accelerate Discovery and Practice Change (ADAPT).
Med Care ; 59(11): 1031-1038, 2021 11 01.
Article en En | MEDLINE | ID: mdl-34510104
ABSTRACT

BACKGROUND:

Illuminating heterogeneity of treatment effect (HTE) within trials is important for identifying target populations for implementation.

OBJECTIVE:

The aim of this study was to examine HTE in a trial of group medical visits (GMVs) for patients with type 2 diabetes and elevated body mass index. RESEARCH DESIGN AND

MEASURES:

Participants (n=263) were randomized to GMV-based medication management plus low carbohydrate diet-focused weight management (WM/GMV; n=127) or GMV-based medication management alone (GMV; n=136) for diabetes control. We used QUalitative INteraction Trees, a tree-based clustering method, to identify subgroups with greater improvement in hemoglobin A1c (HbA1c) and weight from either WM/GMV or GMV. Subgroup predictors included 32 baseline demographic, clinical, and psychosocial factors. Internal validation was conducted to estimate bias in the range of mean outcome differences between arms.

RESULTS:

QUalitative INteraction Trees analyses indicated that for patients who had not previously attempted weight loss, WM/GMV resulted in better glycemic control than GMV (mean difference in HbA1c improvement=1.48%). For patients who had previously attempted weight loss and had lower cholesterol and blood urea nitrogen, GMV was better than WM/GMV (mean difference in HbA1c improvement=1.51%). No treatment-subgroup effects were identified for weight. Internal validation resulted in moderate corrections in mean HbA1c differences between arms; however, differences remained in the clinically significant range.

CONCLUSION:

This work represents a novel step toward targeting care approaches for patients to maximize benefit based on individual patient characteristics.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Visita a Consultorio Médico / Pérdida de Peso / Índice de Masa Corporal / Diabetes Mellitus Tipo 2 / Procesos de Grupo / Hipoglucemiantes Tipo de estudio: Clinical_trials / Prognostic_studies / Qualitative_research Límite: Humans Idioma: En Revista: Med Care Año: 2021 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Visita a Consultorio Médico / Pérdida de Peso / Índice de Masa Corporal / Diabetes Mellitus Tipo 2 / Procesos de Grupo / Hipoglucemiantes Tipo de estudio: Clinical_trials / Prognostic_studies / Qualitative_research Límite: Humans Idioma: En Revista: Med Care Año: 2021 Tipo del documento: Article